TIL Rosenberg Modular Processing Facility (T30 building)

Office Of The Director, Nci

Investigators

Abstract

The NIH / NCI TIL cGMP Modular facility project is a state of the art 10 module standalone facility to be constructed at the NIH campus and will be used to aseptically isolate and expand Tumor Infiltrating Lymphocytes (TILs) cell culture from the primary tumors of enrolled patients as well as patient individualized cellular immunotherapy products for safe infusion into human subjects in compliance with FDA cGMP requirements. The facility opened for cellular processing and manufacturing in February 2022 and provides the much needed cGMP and Cell Processing space and support infrastructure that meets the FDA guidelines for manufacturing Phase 1 and early Phase 2 cellular therapies.